Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
Condition(s):Ovarian Cancer; Cancer of Ovary; Cancer of the Ovary; Ovary Neoplasms; Primary Peritoneal CarcinomaLast Updated:August 27, 2020Terminated
Hide Studies Not Open or Pending
Condition(s):Ovarian Cancer; Cancer of Ovary; Cancer of the Ovary; Ovary Neoplasms; Primary Peritoneal CarcinomaLast Updated:August 27, 2020Terminated
Condition(s):Relapsed Ovarian CancerLast Updated:October 29, 2021Unknown status
Condition(s):Ovarian CancerLast Updated:December 4, 2014Completed
Condition(s):Ovarian CancerLast Updated:July 8, 2022Completed
Condition(s):Ovarian CancerLast Updated:May 30, 2013Completed
Condition(s):Recurrent Ovarian CarcinomaLast Updated:January 2, 2024Active, not recruiting
Condition(s):Ovarian Neoplasms; Recurrent Ovarian Carcinoma; Oligometastatic DiseaseLast Updated:September 27, 2022Recruiting
Condition(s):Ovarian CancerLast Updated:June 22, 2023Terminated
Condition(s):Ovarian NeoplasmsLast Updated:July 25, 2011Completed
Condition(s):Recurrent Ovarian Cancer; Recurrent Fallopian Tube Cancer; Recurrent Primary Peritoneal Cancer; Recurrent Endometrial CancerLast Updated:January 17, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.